Pathology CPT® Codes for 2026 + Modifiers
Feb 14, 2026
Pathology billing in 2026 reflects a major shift toward precision reporting, artificial intelligence integration, and genome-wide molecular diagnostics. Advances in digital slide analytics, Optical Genome Mapping (OGM), and expanded Proprietary Laboratory Analyses (PLA) codes have created new CPT® pathways that replace older bundled or unlisted reporting methods. If your pathology team is still relying on prior-year assumptions, you may already be exposed to preventable denials.
This updated guide outlines the most impactful Pathology CPT® codes and modifiers for 2026, including digital pathology analytics, cytogenomic genome-wide testing, molecular enforcement rules, and compliance clarifications that directly affect reimbursement.
Pathology denials are rarely random—they follow predictable documentation and coding gaps.
We consistently see denials tied to outdated CPT® reporting, improper PLA usage, missing professional/technical component modifiers, and AI services billed without contractual review. We know where payers apply automated edits—and how to correct them before they affect cash flow.
Guarantee: We’ll identify the top denial drivers in your pathology claims and give you a clear plan to eliminate them.
Get My Pathology Denial Snapshot
Contact us to receive a Denial Snapshot showing exactly why claims aren’t paying—and what to change.
Clinical Pathology Core Codes
Routine laboratory services remain foundational in pathology billing but are subject to increased reimbursement scrutiny under 2026 payer efficiency adjustments.
| CPT® Code | Description |
|---|---|
| 80053 | Comprehensive metabolic panel |
| 83036 | Hemoglobin A1c |
| 84443 | Thyroid-stimulating hormone |
| 85025 | Complete blood count with differential |
| 85610 | Prothrombin time |
Heavy Metal Testing Update
Codes 83015 and 83018 have been updated for 2026 to explicitly include additional analytes such as antimony and gadolinium. Ensure laboratory test menus and charge descriptions reflect the revised language to prevent audit discrepancies.
Routine lab codes often deny due to modifier or component errors.
Errors involving -26, -TC, and reference lab reporting frequently trigger automated denials. Even common codes like 80053 or 85025 can reject when billing ownership or processing location is unclear.
Guarantee: We’ll pinpoint component-level billing errors and provide correction steps that prevent recurring denials.
Anatomic Pathology & Surgical Specimens
| CPT® Code | Description |
|---|---|
| 88304 | Surgical pathology, level III |
| 88305 | Surgical pathology, level IV |
| 88307 | Surgical pathology, level V |
| 88309 | Surgical pathology, level VI |
| 88341 | Immunohistochemistry, each additional antibody |
Reflex immunohistochemistry and add-on stains remain under heightened scrutiny in 2026. Standing reflex panels without individualized documentation continue to trigger payer audits.
Reflex Testing Compliance
Each additional stain or molecular test must be supported by documentation explaining how it contributed to establishing or clarifying the final diagnosis. Blanket language such as “reflex per protocol” is frequently insufficient.
Immunohistochemistry add-ons are heavily audited in 2026.
We routinely see denials tied to 88341 and other add-on services when documentation fails to justify medical necessity. Payers are comparing stain frequency patterns across labs.
Guarantee: We’ll identify where add-on utilization may expose your lab to recoupments and show you how to fix it.
AI-Assisted Digital Pathology
AI-based slide analysis tools for pre-screening, quantification, and biomarker detection now have more defined reporting pathways in 2026.
Digital Pathology Analytics Codes
Emerging reporting options—including codes such as X504T—allow separate reporting of algorithmic analysis when payer contracts permit. These services are not universally bundled into 88305.
Important: Billing AI services without confirming contractual recognition may lead to automatic bundling edits.
AI services are new territory—and high risk for incorrect billing.
Many labs assume AI analytics are reimbursable when payer contracts still treat them as bundled. We analyze contract language and payer behavior before claims are submitted.
Guarantee: We’ll determine whether your AI-assisted services are billable—and defensible.
Optical Genome Mapping (OGM)
| CPT® Code | Description |
|---|---|
| 81354 | Cytogenomic genome-wide analysis using optical genome mapping |
Optical Genome Mapping detects large structural variants not visible through standard karyotyping or targeted sequencing.
Critical Update: Reporting OGM using 81479 instead of 81354 in 2026 may result in immediate denial when a specific code exists.
Unlisted molecular codes are fast-track denials in 2026.
Automated crosswalk systems now flag unlisted code usage when a specific CPT® alternative exists. We frequently see preventable denials tied to 81479 misuse.
Guarantee: We’ll identify where unlisted code exposure exists in your workflow and provide correction guidance.
Molecular Pathology & PLA Enforcement
| CPT® Code | Description |
|---|---|
| 81524 | CNS tumor DNA methylation analysis (Category I) |
New PLA codes (0575U–0613U) must be used when applicable. Tier 1, Tier 2, or unlisted codes are not acceptable substitutes when a specific PLA exists.
PLA enforcement is automated—and unforgiving.
Payers now deploy automated logic to cross-reference lab-developed tests with available PLA codes. If the wrong family is used, the claim denies before human review.
Guarantee: We’ll align your molecular test menu with current PLA assignments to prevent unnecessary rejections.
Modifier Updates for 2026
| Modifier | When Used |
|---|---|
| -26 | Professional component |
| -TC | Technical component |
| -90 | Reference laboratory |
| -91 | Repeat diagnostic test |
| -XS | Separate structure |
Mandatory Drug Modifier Enforcement (-JW / -JZ)
-JW must be appended when any portion of a drug is discarded. -JZ must be used when zero waste occurs. Claims lacking one of these modifiers may be automatically rejected.
Modifier errors are a leading cause of pathology denials.
We frequently see incorrect or missing -26, -TC, -90, and drug waste modifiers trigger automated rejections.
Guarantee: We’ll analyze modifier usage patterns and identify repeat denial sources.
Final Thoughts
Pathology billing in 2026 reflects rapid modernization across diagnostics. AI-assisted slide interpretation, genome-wide cytogenomic mapping, PLA enforcement, and stricter modifier requirements require proactive review of both CPT® updates and payer contracts.
Staying current protects reimbursement, reduces audit exposure, and supports innovation without sacrificing compliance.
If pathology denials are slowing your lab down, we can fix that.
Whether your issue is PLA enforcement, AI billing, modifier misuse, or molecular crosswalk denials, we’ve seen these exact patterns across pathology groups nationwide.
Guarantee: We’ll identify your top denial causes and give you a clear corrective plan—so you can get paid faster.
Trademark notice: CPT® is a registered trademark of the American Medical Association.
For informational purposes only.
Contact us
“My husband and I have a small practice but we were looking for a medical billing company to consult us. We originally started with a local company with some satisfaction. However, our biggest problem was that they wanted us to change our existing EMR to software that they worked with. Quest National Services worked with our existing software so that we didn’t have to make expensive changes to our infrastructure. That saved us a lot of time and headache. I would definitely say that was one of the main reasons for why we switched and why we continue to work with Quest. As a small practice, they helped us without draining our resources.”
Adriana C.
